Supernus Pharmaceuticals Inc (SUPN)
36.57
+0.17
(+0.47%)
USD |
NASDAQ |
Nov 08, 16:00
36.57
0.00 (0.00%)
After-Hours: 20:00
Supernus Pharmaceuticals Revenue (TTM): 651.97M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 651.97M |
| June 30, 2024 | 630.16M |
| March 31, 2024 | 597.40M |
| December 31, 2023 | 607.52M |
| September 30, 2023 | 610.54M |
| June 30, 2023 | 634.01M |
| March 31, 2023 | 668.50M |
| December 31, 2022 | 667.24M |
| September 30, 2022 | 658.96M |
| June 30, 2022 | 630.07M |
| March 31, 2022 | 601.35M |
| December 31, 2021 | 579.78M |
| September 30, 2021 | 564.28M |
| June 30, 2021 | 570.95M |
| March 31, 2021 | 556.35M |
| December 31, 2020 | 520.40M |
| September 30, 2020 | 477.29M |
| June 30, 2020 | 424.29M |
| March 31, 2020 | 402.26M |
| December 31, 2019 | 392.76M |
| September 30, 2019 | 408.24M |
| June 30, 2019 | 409.10M |
| March 31, 2019 | 403.94M |
| December 31, 2018 | 408.90M |
| September 30, 2018 | 381.40M |
| Date | Value |
|---|---|
| June 30, 2018 | 358.80M |
| March 31, 2018 | 335.09M |
| December 31, 2017 | 302.24M |
| September 30, 2017 | 276.18M |
| June 30, 2017 | 252.59M |
| March 31, 2017 | 228.39M |
| December 31, 2016 | 215.00M |
| September 30, 2016 | 196.32M |
| June 30, 2016 | 178.87M |
| March 31, 2016 | 162.92M |
| December 31, 2015 | 147.46M |
| September 30, 2015 | 135.01M |
| June 30, 2015 | 118.34M |
| March 31, 2015 | 112.34M |
| December 31, 2014 | 92.68M |
| September 30, 2014 | 71.78M |
| June 30, 2014 | 50.35M |
| March 31, 2014 | 20.95M |
| December 31, 2013 | 12.02M |
| September 30, 2013 | 2.774M |
| June 30, 2013 | 1.608M |
| March 31, 2013 | 1.418M |
| December 31, 2012 | 1.479M |
| September 30, 2012 | 0.432M |
| June 30, 2012 | 0.352M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
392.76M
Minimum
Dec 2019
668.50M
Maximum
Mar 2023
572.30M
Average
599.38M
Median
Revenue (TTM) Benchmarks
| ACADIA Pharmaceuticals Inc | 929.24M |
| Regeneron Pharmaceuticals Inc | 13.85B |
| United Therapeutics Corp | 2.756B |
| Ligand Pharmaceuticals Inc | 133.48M |
| Myomo Inc | 25.24M |